ArticleCancer cell international2026
Spatial transcriptomics and single-cell analyses reveal the role of the cisplatin-resistant gene panel in NSCLC progression and the tumor microenvironment, identifying LOXL2 as a potential therapeutic target.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Targeting the DNA Damage Response in Cancer.MedComm · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-small cell lung cancer (NSCLC) patients often develop resistance to platinum-based chemotherapy, especially cisplatin, leading to treatment failure. This study aimed to identify high-score epithelial cells in tumors within the cisplatin-resistant gene panel (CRGP) and investigate their role in tumor progression and the microenvironment.
methodsUsing cisplatin-resistant cell datasets from GEO and TCGA for NSCLC, we identified the CRGP and its clinical significance. By integrating five single-cell datasets and applying 13 scoring methods, we identified tumor epithelial cells with high CRGP scores (CRGPhighepi). We evaluated drug sensitivity using the BeyondCell algorithm and studied intrinsic mechanisms using Cytotrace, Monocle, SCENIC, and CellCall. Spatial transcriptomics and deconvolution methods identified CRGPhighepi and other cell types. The prognostic model, designated as SuperPCCRGP, was constructed. Subsequent CRGP co-expression network analysis revealed an association between CRGP and LOXL2, implicating their roles in cisplatin resistance. The impact of LOXL2 on cisplatin sensitivity was further validated through in vitro experiments.
resultsCRGP was identified as a potential risk factor for NSCLC prognosis. High CRGP score epithelial cells (CRGPhighepi) activate pathways related to cell cycle and DNA repair and interact with smooth muscle cells. CRGPhighepi exhibits drug resistance to Cisplatin and Paclitaxel. The SuperPC model showed robust predictive performance. LOXL2 was linked to poor prognosis and therapy response. LOXL2 knockdown enhanced cisplatin sensitivity in NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.